- Home
- NFJ vs HROW Comparison
NFJ vs HROW Comparison
Compare NFJ & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- HROW
- Stock Information
- Founded
- NFJ 2005
- HROW 1998
- Country
- NFJ United States
- HROW United States
- Employees
- NFJ N/A
- HROW N/A
- Industry
- NFJ Finance: Consumer Services
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- NFJ Finance
- HROW Health Care
- Exchange
- NFJ Nasdaq
- HROW Nasdaq
- Market Cap
- NFJ 1.2B
- HROW 1.1B
- IPO Year
- NFJ N/A
- HROW N/A
- Fundamental
- Price
- NFJ $12.62
- HROW $34.93
- Analyst Decision
- NFJ
- HROW Strong Buy
- Analyst Count
- NFJ 0
- HROW 7
- Target Price
- NFJ N/A
- HROW $61.83
- AVG Volume (30 Days)
- NFJ 223.5K
- HROW 368.3K
- Earning Date
- NFJ 01-01-0001
- HROW 08-06-2025
- Dividend Yield
- NFJ 9.01%
- HROW N/A
- EPS Growth
- NFJ N/A
- HROW N/A
- EPS
- NFJ N/A
- HROW N/A
- Revenue
- NFJ N/A
- HROW $212,858,000.00
- Revenue This Year
- NFJ N/A
- HROW $44.89
- Revenue Next Year
- NFJ N/A
- HROW $38.22
- P/E Ratio
- NFJ N/A
- HROW N/A
- Revenue Growth
- NFJ N/A
- HROW 53.49
- 52 Week Low
- NFJ $10.45
- HROW $20.85
- 52 Week High
- NFJ $12.86
- HROW $59.23
- Technical
- Relative Strength Index (RSI)
- NFJ 66.98
- HROW 70.24
- Support Level
- NFJ $12.16
- HROW $30.81
- Resistance Level
- NFJ $12.69
- HROW $33.27
- Average True Range (ATR)
- NFJ 0.11
- HROW 1.37
- MACD
- NFJ 0.02
- HROW 0.09
- Stochastic Oscillator
- NFJ 89.23
- HROW 88.78
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.